<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05627440</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00003095</org_study_id>
    <secondary_id>1R01HL167113-01</secondary_id>
    <nct_id>NCT05627440</nct_id>
  </id_info>
  <brief_title>A SkeleTal Muscle Recovery Intervention With Dietary Protein in Heart Failure</brief_title>
  <acronym>ASTRID-HF</acronym>
  <official_title>A SkeleTal Muscle Recovery Intervention With Dietary Protein in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe skeletal wasting and catabolic weight loss are highly common among patients with heart&#xD;
      failure with reduced ejection fraction (HFrEF). This prospective randomized controlled trial&#xD;
      will compare changes in the muscle mass in the arms and the legs (appendicular lean mass) in&#xD;
      patients with HFrEF randomized between 3 groups of no, low- or high-dose protein&#xD;
      supplementation. The dietary protein supplementation will be Ensure(R) products manufactured&#xD;
      by Abbott Nutrition. The Investigators hypothesize that skeletal muscle wasting in HFrEF is&#xD;
      promoted by neurohumoral activation of catabolic metabolism (such as GDF-15 and ActRII&#xD;
      pathways) and can be at least partially reversed by increased dietary protein intake. It is&#xD;
      anticipated that this study will determine whether dietary protein supplementation helps to&#xD;
      prevent muscle wasting and will advance understanding of the GDF-15 and ActRII muscle wasting&#xD;
      pathways.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Appendicular Lean Mass (ALM)</measure>
    <time_frame>6 month study visit</time_frame>
    <description>ALM as measured by dual X-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appendicular Lean Mass (ALM)</measure>
    <time_frame>3 month study visit</time_frame>
    <description>ALM as measured by dual X-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein intake</measure>
    <time_frame>6 month study visit</time_frame>
    <description>Dietary protein intake in g/kg/day, averaged over 3 days, which is calculated by entering recorded dietary intake from facilitate food record into the Food Processor® software</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein intake</measure>
    <time_frame>3 month study visit</time_frame>
    <description>Dietary protein intake in g/kg/day, averaged over 3 days, which is calculated by entering recorded dietary intake from facilitated food record into the Food Processor® software</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip strength</measure>
    <time_frame>6 month study visit</time_frame>
    <description>Strength in dominant hand assessed with 3 attempts using a hydraulic hand dynamometer in the dominant hand (Baseline® Evaluation Instruments Fabrication Enterprises Inc., Irvington NY) and the mean calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip strength</measure>
    <time_frame>3 month study visit</time_frame>
    <description>Strength in dominant hand assessed with 3 attempts using a hydraulic hand dynamometer in the dominant hand (Baseline® Evaluation Instruments Fabrication Enterprises Inc., Irvington NY) and the mean calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk test (6MWT)</measure>
    <time_frame>6 month study visit</time_frame>
    <description>6-minute walk test measured over 100-foot laps, with 0 feet assigned if no independent ambulation is possible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk test (6MWT)</measure>
    <time_frame>3 month study visit</time_frame>
    <description>6-minute walk test measured over 100-foot laps, with 0 feet assigned if no independent ambulation is possible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short physical performance battery (SPPB)</measure>
    <time_frame>6 months</time_frame>
    <description>SPPB assesses balance, gait, strength, and endurance, by recording the ability to stand for up to 10 seconds with feet in the side-by-side, semi-tandem, and tandem positions; time to complete a 4-meter walk; and time to rise from a chair and return to the seated position 5 times</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short physical performance battery (SPPB)</measure>
    <time_frame>3 months</time_frame>
    <description>SPPB assesses balance, gait, strength, and endurance, by recording the ability to stand for up to 10 seconds with feet in the side-by-side, semi-tandem, and tandem positions; time to complete a 4-meter walk; and time to rise from a chair and return to the seated position 5 times</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fat free mass (FFM)</measure>
    <time_frame>6 months</time_frame>
    <description>FFM as measured by dual X-ray absorptiometry (DXA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fat free mass (FFM)</measure>
    <time_frame>3 months</time_frame>
    <description>FFM as measured by dual X-ray absorptiometry (DXA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fat mass (FM)</measure>
    <time_frame>6 months</time_frame>
    <description>FM as measured by dual X-ray absorptiometry (DXA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fat mass (FM)</measure>
    <time_frame>3 months</time_frame>
    <description>FM as measured by dual X-ray absorptiometry (DXA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>6 months</time_frame>
    <description>Bodyweight</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>3 months</time_frame>
    <description>Bodyweight</description>
  </other_outcome>
  <other_outcome>
    <measure>Simplified Nutritional Appetite Questionnaire (SNAQ)</measure>
    <time_frame>6 months</time_frame>
    <description>Malnutrition risk assessment tool</description>
  </other_outcome>
  <other_outcome>
    <measure>Simplified Nutritional Appetite Questionnaire (SNAQ)</measure>
    <time_frame>3 months</time_frame>
    <description>Malnutrition risk assessment tool</description>
  </other_outcome>
  <other_outcome>
    <measure>Mini-Nutritional Assessment-Short Form (MNA-SF)</measure>
    <time_frame>6 months</time_frame>
    <description>Malnutrition risk assessment tool</description>
  </other_outcome>
  <other_outcome>
    <measure>Mini-Nutritional Assessment-Short Form (MNA-SF)</measure>
    <time_frame>3 months</time_frame>
    <description>Malnutrition risk assessment tool</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjective Global Assessment (SGA)</measure>
    <time_frame>6 months</time_frame>
    <description>Semi-quantified assessment of cachexia per physical examination</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjective Global Assessment (SGA)</measure>
    <time_frame>3 months</time_frame>
    <description>Semi-quantified assessment of cachexia per physical examination</description>
  </other_outcome>
  <other_outcome>
    <measure>Growth Differentiation Factor (GDF)-15</measure>
    <time_frame>3 months</time_frame>
    <description>Inflammatory and growth regulation cytokine blood concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Growth Differentiation Factor (GDF)-15</measure>
    <time_frame>6 months</time_frame>
    <description>Inflammatory and growth regulation cytokine blood concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Activin A and Follistatin-related gene (FSTL)-3</measure>
    <time_frame>3 months</time_frame>
    <description>Muscle growth regulation pathway blood concentrations</description>
  </other_outcome>
  <other_outcome>
    <measure>Activin A and Follistatin-related gene (FSTL)-3</measure>
    <time_frame>6 months</time_frame>
    <description>Muscle growth regulation pathway blood concentrations</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Heart Failure</condition>
  <condition>Muscle Atrophy</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 g/day protein supplementation (1 Ensure Max Protein® bottle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham comparator arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>9 g/day protein supplementation (1 Ensure Original® bottle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>0 g/day protein supplementation (no Ensure bottles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ensure Max Protein</intervention_name>
    <description>Ensure Max Protein, 1 bottle daily (330 mL), 30 grams protein</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ensure Original</intervention_name>
    <description>Ensure Original, 1 bottle daily (237 mL), 9 grams protein</description>
    <arm_group_label>Sham comparator arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Left ventricular ejection fraction (LVEF) ≤40%, New York Heart Association (NHYA)&#xD;
             class II to IV symptoms or N-terminal pro B-natriuretic peptide (NT-proBNP) &gt;300 pg/mL&#xD;
&#xD;
          2. Age 18 years to 100 years, inclusive&#xD;
&#xD;
          3. Receiving guideline-directed medical therapy (GDMT), unless contraindicated or not&#xD;
             tolerated&#xD;
&#xD;
          4. Any of the following markers of severe HF within prior 12 months: i) Inotropic&#xD;
             therapy; ii) 1 or more HF hospitalizations; iii) LVEF ≤25%; iv) Peak oxygen&#xD;
             consumption (VO2) &lt;50% predicted or ≤16 mL/kg/min; v) 6-minute walk distance &lt;300&#xD;
             meters; vi) Unintentional weight loss &gt;5% of bodyweight over the past year; vii)&#xD;
             Moderate or severe muscle wasting on physical examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy, planning to become pregnant, or women of reproductive potential unwilling&#xD;
             to complete pre-DXA urine pregnancy test before first DXA or randomization&#xD;
&#xD;
          2. History of left ventricular assist device (LVAD), heart transplantation, or estimated&#xD;
             glomerular filtration rate (eGFR) &lt;20 mL/min/1.73 m2&#xD;
&#xD;
          3. An identified clinical disorder associated with skeletal muscle weakness/wasting&#xD;
             (e.g., muscular dystrophy, mitochondrial disorder, active cancer, modified Rankin&#xD;
             score greater or equal to 4 post-stroke)&#xD;
&#xD;
          4. Milk allergy, protein allergy, lactose intolerance, and galactosemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Lovegreen</last_name>
      <phone>617-636-5000</phone>
      <email>OLovegreen@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Amanda R Vest, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 17, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2022</study_first_posted>
  <last_update_submitted>April 24, 2023</last_update_submitted>
  <last_update_submitted_qc>April 24, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data sharing plans will be reviewed by the Tufts Health Sciences IRB and no identifiable participant data will be shared outside Tufts Medical Center. A data use agreement (DUA) will be completed between the PI and collaborating sites.</ipd_description>
    <ipd_time_frame>After primary and secondary analyses have been completed and the major findings for each Aim accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Due to the small sample size and single center location of the subjects, there remains a potential for deductive disclosure of subjects with unique clinical characteristics. Thus, the DUA will include language requiring: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

